Organization
University of Pennsylvania
186 clinical trials
127 abstracts
7 posters
Abstract
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.Org: Department of Neurosurgery, Prince of Wales Hospital, Department of Radiation Oncology, Baptist Health South Florida, Perelman School of Medicine, Department of Radiology,
Abstract
PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study.Org: University of Pennsylvania, Hospital of the University of Pennsylvania,
Abstract
Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.Org: Wake Forest University Department of General Internal Medicine, Wake Forest Baptist Health, University of Pennsylvania, OncoNano Medicine, Allegheny Health Network Cancer Institute,
Abstract
Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Vanderbilt University Medical Center, University of Utah, Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Merck & Co., Inc.,
Abstract
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.Org: Miami Cancer Institute, Poznan University of Medical Sciences, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, General University Hospital in Prague,
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Breast cancer risk associated with missense variants in BRCA2.Org: Ambry Genetics, Harvard T.H. Chan School of Public Health, Sierra Madre, Abramson Cancer Center, University of Pennsylvania,
Abstract
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.Org: Weill Cornell Medicine, Mount Sinai Hospital-Breast Medical Oncology, Massachusetts General Hospital, UM/Sylvester Comprehensive Cancer Center, UNC Patient Advocates for Research Council,
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.Org: The University of Texas MD Anderson Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, Baylor College of Medicine, University of Pennsylvania, Central Connecticut Radiation Oncology,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).Org: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Baylor College of Medicine, Mayo Hosp, Memorial Sloan Kettering Cancer Center,
Abstract
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.Org: Department of Medicine, University of Chicago, Johns Hopkins Medicine, University of Pennsylvania, Emory University Winship Cancer Institute, Hollings Cancer Center,
Abstract
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Center for Cellular Immunotherapies, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
Radiation dose escalation and local control for intermediate-risk rhabdomyosarcoma on ARST1431: A report from the Children’s Oncology GroupOrg: Memorial Sloan Kettering Cancer Center, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, The Hospital for Sick Children, Cincinnati Children's Hospital Medical Center, University of Pennsylvania,
Abstract
Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS).Org: University of Chicago Pritzker School of Medicine, Fox Chase Cancer Center, University of Pennsylvania, Columbia University Mailman School of Public Health, New York, NY, Duke University Medical Center,
Abstract
CINSARC score use in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in the Children’s Oncology Group (COG) studies ARST0332 and ARST1321.Org: Children's Hospital of Philadelphia, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Children's Oncology Group Statistics and Data Center, University of Florida, Massachusetts General Hospital, Seattle Children's Hospital,
Abstract
SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).Org: Children's Hospital of Philadelphia, Mayo Clinic, Department of Population Health Sciences, Weill Cornell Medicine, Children’s Hospital Los Angeles,
Abstract
Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer.Org: Massachusetts General Hospital, Division of Hematology and Oncology/Department of Medicine, Boston, MA, Harvard Medical School, University of Pennsylvania,
Abstract
BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Tennessee Oncology, PLLC,
Abstract
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Yale University School of Medicine and Yale Cancer Center, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Johns Hopkins University, University of Pennsylvania Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center,
Abstract
Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.Org: Onc.AI, Pfizer Inc., Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital,
Abstract
Disparities in stage at presentation for disaggregated Asian American, Native Hawaiian, and Pacific Islander (AANHPI) groups with breast cancer.Org: University of Pennsylvania, Harvard University, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University of Rochester, University of Pittsburgh,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Evaluating the association between radiomic features on breast MRI and dormant tumor cell presence in the SURMOUNT trial.Org: Columbia University Medical Center, Hospital of the University of Pennsylvania, University of Pennsylvania, Perelman Center for Advanced Medicine, Center for Biomedical Image Computing and Analytics (CBICA),
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.Org: Cancer Research @UCC, Brown University - ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Saint Vincent Hospital Cancer Center Green Bay, University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
Current diagnostic guidelines and perpetuation of inequities in ovarian cancer: A National Cancer Database study.Org: University of Pennsylvania, University of Pennsylvania Perelman School of Medicine,
Abstract
Post-market study requirements and associations with timely submission and regulatory action for oncology drugs receiving accelerated approval, 2011-2023.Org: University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Perelman School of Medicine, Carey Law School,
Abstract
Start low, go slow: A systematic review and meta-analysis of upfront tailored treatment dosing in older adults with advanced cancer.Org: University of Pennsylvania, Penn Medicine Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,
Abstract
ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.Org: Massachusetts General Hospital, Brown University School of Medicine-Rhode Island Hospital, University of Washington School of Medicine, Wake Forest University Department of General Internal Medicine, Icahn School of Medcn At Mount Sinai,
Abstract
Deciphering pediatric low-grade glioma trajectories: Deep learning–based volumetrics for patients under surveillance.Org: Brigham and Women's Hospital, Division of Neuroradiology, Perelman School of Medicine, University of Pennsylvania, Department of Radiology,
Clinical trial
Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic FibrosisStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
11C-Acetate Position Emission Tomography/Computerized Tomography (PET/CT) Imaging As a Biomarker of Amyloid-Induced NeuroinflammationStatus: Terminated, Estimated PCD: 2022-02-28
Clinical trial
Promoting Recovery After STroke With AmantadineStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Levothyroxine Dosing in Older IndividualsStatus: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Trial of a Topical Nitroglycerin Challenge to Detect Reversible Microcirculatory Dysfunction in Patients With Circulatory Shock.Status: Completed, Estimated PCD: 2022-02-01
Clinical trial
A Randomized, Double-Blind, Multi-Center Comparative Effectiveness Study of Spironolactone Versus Doxycycline Hyclate for the Treatment of Acne in WomenStatus: Recruiting, Estimated PCD: 2025-07-31
Abstract
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.Org: University of California Comprehensive Cancer Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA, University of Texas MD Anderson Cancer Center, Houston, TX, UC Davis, Davis, CA, Masonic Cancer Center, Minneapolis, MN,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Clinical trial
Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative DiseaseStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients With Resectable HPV-negative Head/Neck Squamous Cell Carcinoma (HNSCC)Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
POM PROM: Pitocin or Oral Misoprostol for PROM IOL in Nulliparous Women With Unfavorable Cervical ExamsStatus: Completed, Estimated PCD: 2022-12-08
Clinical trial
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2036-01-01
Clinical trial
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for WhomStatus: Recruiting, Estimated PCD: 2026-02-15
Clinical trial
Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence ApproachStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
APPLE: Aspirin to Prevent Pregnancy Loss and PreeclampsiaStatus: Not yet recruiting, Estimated PCD: 2029-05-01
Clinical trial
Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use DisorderStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Abstract
Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers.Org: University of Pennsylvania, Guardant Health Inc.,
Abstract
Features of HPV+ OPSCC predictive of recurrence identified by transcriptional profiling of a case-control cohort.Org: University of Pennsylvania, The University of Chicago Medicine Center for Advanced Care at Orland Park,
Abstract
Immune-related adverse events after 2 years in patients with advanced non-small-cell lung cancer receiving extended immune checkpoint inhibitor therapy.Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania,
Abstract
Off-label use of checkpoint inhibitor (CPI) monotherapy in PD-L1–negative or unknown recurrent/metastatic head and neck cancer (R/M HNSCC).Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Informatics,
Abstract
Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma.Org: Stanford Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,
Abstract
Long term cardiovascular adverse outcomes in testicular cancer survivors: Real-world U.S. population-based study.Org: University of Pennsylvania, Conshohocken, Abramson Cancer Center, Indian University Simon Comprehensive Cancer Center, University Medical Center Groningen,
Abstract
BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, University of Pennsylvania, Hospital of the University of Pennsylvania, University of California, San Francisco,
Abstract
Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Michigan, Rogel Comprehensive Cancer Center,
Abstract
Racial and ethnic differences in patient-reported provider communication among patients with cancer.Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Memorial Sloan Kettering Cancer Center,
Abstract
Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.Org: Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Pennsylvania, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center,
Abstract
Combined NF2/PTEN mutations as predictors of meningioma aggressiveness.Org: University of Pennsylvania,
Abstract
Human-AI teams to improve accuracy and timeliness of oncology trial prescreening: Preplanned interim analysis of a randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine,
Clinical trial
The AUDYT Trial: An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsToniaStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib In Combination With Everolimus In Subjects With Relapsed/Refractory Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory DrugsStatus: Terminated, Estimated PCD: 2022-09-01
Abstract
Association of Fried’s frailty phenotype, but not the clinical frailty scale, with overall survival in older adults with acute myeloid leukemia.Org: Division of Geriatrics, University of Pennsylvania, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Pennsylvania Health System,
Clinical trial
Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular ReactivityStatus: Completed, Estimated PCD: 2022-08-31
Abstract
Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,
Clinical trial
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-M503Status: Recruiting, Estimated PCD: 2029-02-01
Clinical trial
Fecal Microbial Transplantation (FMT) For the Treatment of Fecal Incontinence in WomenStatus: Terminated, Estimated PCD: 2023-01-18
Clinical trial
Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort StudyStatus: Not yet recruiting, Estimated PCD: 2025-07-15
Clinical trial
Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal CancerStatus: Terminated, Estimated PCD: 2022-02-22
Clinical trial
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence Among HIV-infected SmokersStatus: Completed, Estimated PCD: 2022-04-21
Clinical trial
Study of Immune Responses to Influenza VaccinationStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase 2 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant Consolidation and Maintenance for Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-07-11
Clinical trial
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace Positron Emission Tomography (PET/CT)Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human SubjectsStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Randomized Multicenter Study for Isolated Skin VasculitisStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over TrialStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Pilot, Open-Label Study Evaluating the Safety and Feasibility of Using Rescue Therapies for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like SyndromeStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Measurement of Pulmonary Inflammation Using 18F-NOS Positron Emission Tomography (PET/CT) in E-cigarette UsersStatus: Recruiting, Estimated PCD: 2024-10-23
Clinical trial
Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand PI-2620Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM): Can it Increase the Success of Transition to Naltrexone?Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
A Study to Evaluate the Safety and Efficacy of Indocyanine Green for Intraoperative Molecular Imaging of Solid Tumors (TumorGlow™)Status: Not yet recruiting, Estimated PCD: 2026-01-14
Clinical trial
A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory MyelomaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers With HIVStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use DisorderStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Safety, PK/PD, Acceptability, and Desirability of a Novel HIV Prevention Douche Among Adolescent Men (DREAM)Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
Stress and Inflammation in the Pathophysiology of Late Life DepressionStatus: Completed, Estimated PCD: 2022-07-18
Clinical trial
Effects of Ketone Ester on Brain Function and Alcohol Consumption in Alcohol Use DisorderStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Terminated, Estimated PCD: 2024-03-26
Clinical trial
A Phase II Study Evaluating the Efficacy and Safety of Niraparib and Tumor-Treating Fields in Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use DisorderStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use DisorderStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2037-12-01
Clinical trial
Phase 2 Randomized Controlled Trial of Sildenafil Citrate for Treatment of Cerebrovascular Dysfunction in Chronic Traumatic Brain InjuryStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Developing Oral LT3 Therapy For Heart Failure With Reduced Ejection FractionStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
Testing the Reward-Drinker Hypothesis of Naltrexone Using an Extended-Release FormulationStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 1 Study of INO-A002 in Healthy Dengue Virus-naive AdultsStatus: Completed, Estimated PCD: 2022-10-03
Clinical trial
Randomized Trial of Universal vs. Guideline-directed Germline Testing Among Young Adults With CancerStatus: Recruiting, Estimated PCD: 2025-01-02
Clinical trial
Phase I Study of CART-PSMA-TGFβRDN Cells in Patients With Advanced Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2038-09-08
Clinical trial
Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
Phase I Trial of TmCD19-IL18 CAR T Cells in Patients With Relapsed or Refractory CD19+ CancersStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
SSRI Effects on Depression and Immunity in HIV/AIDSStatus: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Phase 1/2, Randomized Double-blind Placebo-Controlled Trial to Test the Safety and Antiviral Activity of ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Nanozyme-mediated Catalysis for Clinical Treatment of Biofilm InfectionsStatus: Completed, Estimated PCD: 2022-03-10
Clinical trial
Prospective Evaluation of Minimally Invasive Facial Cosmetic Procedures Through Measured Volumetric Changes and Patient Reported OutcomesStatus: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Status: Recruiting, Estimated PCD: 2036-05-01
Clinical trial
Three Approaches to Maintenance Therapy for Chronic Insomnia in Older AdultsStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
Characterization of Cardiac Electrophysiological Effects of Autonomic NeuromodulationStatus: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel TherapyStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid WithdrawalStatus: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) Alone and When Co-administered With Humanized Anti-CD19 Chimeric Antigen Receptor Redirected T Cells (huCART19) In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2036-01-01
Clinical trial
To Serenade or To Sedate? That is Still The Question - A Followup Trial On Anxiolytic Options Before Peripheral Nerve BlocksStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase II, Randomized Trial to Evaluate the Optimal Dosing of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Recurrent Clostridium Difficile InfectionStatus: Terminated, Estimated PCD: 2021-08-11
Clinical trial
A Phase II, Randomized Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Severe or Severe-Complicated/Fulminant Clostridium Difficile InfectionStatus: Terminated, Estimated PCD: 2021-11-21
Clinical trial
Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Cardiac Amyloidosis Using Positron Emission Tomography (PET/CT)Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant CandidatesStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot StudyStatus: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) TrialStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRIStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)Status: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
Adrenergic Contribution to Glucose Counterregulation in Islet TransplantationStatus: Active (not recruiting), Estimated PCD: 2019-04-30
Clinical trial
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy AdultsStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluotriopride ([18F]FTP) by PET/CTStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Imaging Inflammation in Individuals With Alcohol Use Disorder: an [18F]NOS StudyStatus: Recruiting, Estimated PCD: 2027-03-15
Clinical trial
A Dose Finding Study for Fat-Induced Insulin Resistance in Healthy VolunteersStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in HumanStatus: Active (not recruiting), Estimated PCD: 2023-10-17
Clinical trial
A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella AreaStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Effects of the Contraceptive Implant in Women With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
A Pilot Study of T Cells Genetically Modified by Zinc Finger Nucleases SB-728mR and CD4 Chimeric Antigen Receptor in HIV-infected SubjectsStatus: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic CancerStatus: Completed, Estimated PCD: 2024-02-12
Clinical trial
The Use of Peri-Operative Intravenous Estrogen for the Mitigation of Ischemia Reperfusion Injury in the Setting of Renal TransplantationStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's SyndromeStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of EnthesitisStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human ChronobiomeStatus: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart FailureStatus: Completed, Estimated PCD: 2023-06-01
Clinical trial
Effects of Opioid Use Disorder and Non-fatal Overdose on Tau Pathology; a [18F]PI-2620 PET/CT StudyStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Developing Oral LT3 Therapy For Heart Failure With Preserved Ejection FractionStatus: Completed, Estimated PCD: 2023-10-31
Clinical trial
Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 MutationsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Evaluation of in Vivo Neuroinflammation Using 18F-NOS Positron Emission Tomography (PET/CT) in HIV Positive and Negative Subjects With Opioid Use Disorder and Healthy ControlsStatus: Recruiting, Estimated PCD: 2025-12-07
Clinical trial
Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1Status: Terminated, Estimated PCD: 2021-06-17
Clinical trial
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain InjuryStatus: Not yet recruiting, Estimated PCD: 2027-08-31
Clinical trial
Trimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis With PolyangiitisStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
The Effects of Solriamfetol and CBT-I (Alone and in Combination) on Sleep Continuity, Sleepiness, Fatigue, and Performance in Patients With Insomnia DisorderStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Phase I Trial of Programmed Allogeneic CRISPR-edited T Cells (PACE) Gene Edited to Eliminate Endogenous TCR, HLA-class I and HLA-class II and Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaStatus: Withdrawn, Estimated PCD: 2025-01-01
Clinical trial
Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2019-08-21
Clinical trial
Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted TreatmentStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Evaluation of in Vivo Neuroinflammation in Alzheimer's Disease Using Novel Positron Emission Tomography (PET/CT) ImagingStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)Status: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
Randomized Study Of Cranial Blocks For Postoperative Anesthesia To Reduce Pain And Postoperative Opioid UsageStatus: Terminated, Estimated PCD: 2021-07-20
Clinical trial
Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast CancerStatus: Completed, Estimated PCD: 2018-08-13
Clinical trial
Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic LeukemiaStatus: Terminated, Estimated PCD: 2018-12-12
Clinical trial
The Influence of Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine AddictionStatus: Active (not recruiting), Estimated PCD: 2025-11-22
Clinical trial
Retreatment With CTL019/CTL119 in Patients With Late Relapse of B-Cell LymphomasStatus: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
Pilot Study of a Multi-System Analysis of Opioid Receptor BindingStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Phase 2 Study Of Autologous T Cells Engineered To Express an Anti-CD19 Chimeric Antigen Receptor (CART-19) Following First-line Autologous Stem Cell Transplantation for High-risk Multiple MyelomaStatus: Terminated, Estimated PCD: 2019-02-01
Clinical trial
Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple MyelomaStatus: Recruiting, Estimated PCD: 2041-05-01
Clinical trial
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity StudyStatus: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II, Randomized Trial to Test the Effect of Povidone-iodine 0.5% as Mouthwash/Gargle on SARS-CoV-2 Load (COVID 19) as an Adjuvant Infection Control Measure in Dental PracticeStatus: Completed, Estimated PCD: 2022-07-07
Clinical trial
Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients: Prospective Treatment Trial With Topical Glycolic Acid and HPV Genotype CharacterizationStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ GlioblastomaStatus: Terminated, Estimated PCD: 2018-04-04
Clinical trial
Influenza Vaccine Responses in the Setting of Melanoma TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2016-11-01
Clinical trial
PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based TherapyStatus: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)Status: Completed, Estimated PCD: 2009-03-01
Clinical trial
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Status: Completed, Estimated PCD: 2017-12-13
Clinical trial
Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaStatus: Completed, Estimated PCD: 2015-07-01
Clinical trial
Rapid Initiation of Buprenorphine/Naloxone to Optimize MAT Utilization in PhiladelphiaStatus: Completed, Estimated PCD: 2022-03-30
Clinical trial
Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid CancerStatus: Recruiting, Estimated PCD: 2039-06-01
Clinical trial
Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRζ And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCTStatus: Completed, Estimated PCD: 2015-09-01
Clinical trial
A Validation Study Evaluating the Use of 3H-Cholesterol Bound to Albumin as a Method to Assess Reverse Cholesterol Transport in Subjects With Monogenic Diseases Affecting HDL MetabolismStatus: , Estimated PCD: 2024-07-31
Clinical trial
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasStatus: Completed, Estimated PCD: 2019-09-16
Clinical trial
Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)Status: Terminated, Estimated PCD: 2020-02-29
Clinical trial
Open-Labeled Trial Of Direct-Acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive DonorsStatus: Completed, Estimated PCD: 2022-03-01
Clinical trial
Open-Labeled Trial Of Direct-acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Lung Transplants From Hepatitis C-Positive DonorsStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
Evaluation of D3 Receptor Occupancy Using [18F]FLUORTRIOPRIDE ([18F]FTP) PET/CTStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2038-09-01
Clinical trial
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated GlioblastomaStatus: Completed, Estimated PCD: 2021-02-27
Clinical trial
Matching Perfusion and Metabolic Activity in HFpEFStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Open Label Trial of Tolerability and Efficacy of Oral Letermovir for CMV Prophylaxis Among Heart and Lung Transplant RecipientsStatus: Recruiting, Estimated PCD: 2026-08-15
Clinical trial
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive DysfunctionStatus: Completed, Estimated PCD: 2022-05-31
Clinical trial
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseStatus: Completed, Estimated PCD: 2018-12-01
Clinical trial
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaStatus: Terminated, Estimated PCD: 2017-09-01
Clinical trial
Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast CarcinomaStatus: Terminated, Estimated PCD: 2020-03-27
Clinical trial
Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast CancerStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2036-03-01
Clinical trial
Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLLStatus: Terminated, Estimated PCD: 2018-10-15
Clinical trial
Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic LeukemiaStatus: Completed, Estimated PCD: 2018-04-26
Clinical trial
Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease StudyStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Olanzapine Augmentation of Buprenorphine-naloxone Treatment in OUD Patients With Comorbid Symptoms of Serious Mental Illness (SMI): A Prospective Open-label Single-arm 9-week StudyStatus: Withdrawn, Estimated PCD: 2023-01-30
Clinical trial
Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance HemodialysisStatus: Completed, Estimated PCD: 2021-09-02
Clinical trial
A Randomized, Double Blind Comparison of the Total Dose of 1.0% Lidocaine With 1:100,000 Epinephrine Versus 0.5% Lidocaine With 1:200,000 Epinephrine Needed to Achieve Effective Anesthesia During Mohs Micrographic SurgeryStatus: Completed
Clinical trial
Effect of Nutritional Ketosis on Alcohol MetabolismStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized, Placebo-Controlled Mechanistic Clinical Trial of Colchicine in Patients Undergoing Femoral EndarterectomyStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Study of Human Multi-Sensory Integration: A Neurophysiologic Correlate of Conscious PerceptionStatus: , Estimated PCD: 2023-05-01
Clinical trial
A Phase II Study of the Anti-GITR Agonist INCAGN1876 and the PD-1 Inhibitor INCMGA00012 in Combination With Stereotactic Radiosurgery in Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2022-09-08
Clinical trial
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15Status: Recruiting, Estimated PCD: 2028-07-31
Clinical trial
The Effect of Liposomal Bupivacaine on the Quality of Recovery in Patients Undergoing Shoulder ArthroscopyStatus: Withdrawn, Estimated PCD: 2022-06-27
Clinical trial
Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSOStatus: Completed, Estimated PCD: 2022-04-30
Clinical trial
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin InhibitionStatus: , Estimated PCD: 2024-06-01
Clinical trial
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Topical Anti-Androgens in Pilonidal Sinus DiseaseStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm RepairStatus: Not yet recruiting, Estimated PCD: 2028-11-01
Clinical trial
Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus ErythematosusStatus: Completed, Estimated PCD: 2009-07-01
Clinical trial
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
The Analgesic Efficacy of Adding the IPACK Block to a Multimodal Analgesia Protocol for Primary Total Knee ArthroplastyStatus: Completed, Estimated PCD: 2019-08-27
Clinical trial
SGLT2i and KNO3 in HFpEF - The SAK HFpEF TrialStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Prevention of Fall in Older Adults With Overactive BladdarStatus: Completed, Estimated PCD: 2017-07-19
Clinical trial
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCRζ And 4-1BB Signaling Domains In Combination With CD33KO-HSPC In Subjects With Refractory Or Relapsed Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2029-02-23
Clinical trial
Short- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial StatusStatus: Active (not recruiting), Estimated PCD: 2025-07-15
Clinical trial
Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological AgingStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Pulmonary Hypertension and Anastrozole Trial (PHANTOM)Status: Completed, Estimated PCD: 2022-07-22
Clinical trial
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney RecipientsStatus: Recruiting, Estimated PCD: 2025-05-18
Clinical trial
A Phase II Randomized Trial to Evaluate the Impact of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products on Recipient and Environmental Colonization With Multidrug-Resistant OrganismsStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Rapid Outpatient Low-dose Initiation of Buprenorphine for Individuals With OUD Using FentanylStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Abstract
Association between state Medicaid policies and accrual of Black and Hispanic patients to cancer clinical trials.Org: Perelman School of Medicine, University of Pennsylvania, Weill Medical College, Cornell University, Medidata AI,
Abstract
Patient- and clinician-directed implementation strategies to improve serious illness communication for high-risk patients with cancer: A cluster-randomized pragmatic trial.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, School of Nursing, University of Alabama at Birmingham, Birmingham, AL, Mailman School of Public Health, Columbia University,
Abstract
Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC).Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,
Abstract
Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.Org: University of Pennsylvania, Abramson Cancer Center, Penn Presbyterian Medical Center, Perelman School of Medicine,
Abstract
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.Org: Netherlands Cancer Institute, Melanoma Institute Australia, Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Netherlands Cancer Institute (NKI-AVL),
Abstract
A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.Org: Hospital of the University of Pennsylvania, University of Pennsylvania,
Abstract
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,
Abstract
Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.Org: University of California San Francisco, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Dana-Farber/Brigham and Women's Cancer Center, San Francisco VA Medical Center, University of Florida Health Shands Hospital,
Abstract
Neoplasia detection via colonoscopic surveillance among young patients with MSH6 and PMS2-associated Lynch syndrome.Org: Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Dana-Farber Cancer Institute, University of Pennsylvania Perelman School of Medicine,
Abstract
End-of-life spending analysis of randomized trial of machine learning nudges to prompt serious illness communication among patients with cancer.Org: Perelman School of Medicine, University of Pennsylvania, Ascension Health, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute,
Abstract
Association of remote, longitudinal patient-reported outcomes (PROs) and step counts with hospitalization or death among patients with advanced cancer undergoing chemotherapy: Secondary analysis of the PROStep randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Penn Medicine at Lancaster General Health, Ascension Health,
Abstract
Long term efficacy of psilocybin in cancer patients with major depressive disorder (MDD).Org: Sunstone Therapies, Columbia University - Mailman School of Public Health, University of Pennsylvania,
Abstract
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).Org: Gustave Roussy and Paris Saclay University, Villejuif, France, Faculty of Medicine, Cairo University, Villejuif / Kremlin-Bicêtre, France, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.Org: David Geffen School of Medicine at University of California Los Angeles (UCLA), Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Veterans Affairs Greater Los Angeles Healthcare System, VA National Oncology Program and Durham VA Medical Center, University of Pennsylvania,
Abstract
Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Miami Neuroscience Institute, Mayo Clinic, University of California Irvine,
Abstract
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.Org: Perelman School of Medicine, University of Pennsylvania, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,
Abstract
Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis.Org: Memorial Sloan Kettering Cancer Center, Elevance Health, Humana, CVS Health, Texas A&M University,
Abstract
Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Wake Forest University School of Medicine, University of Alabama-Birmingham, Henry Ford Hospital, University of Pittsburgh, Pittsburgh, PA,
Abstract
Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).Org: Abramson Cancer Center at the University of Pennsylvania, University of Pennsylvania, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.Org: Johns Hopkins University School of Medicine, University of Texas MD Anderson Cancer Center, University of Pennsylvania, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, University of Texas at MD Anderson Cancer Center,
Abstract
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Abstract
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).Org: University of Pennsylvania, Stanford Cancer Center,
Abstract
Hospital Anxiety and Depression Scale (HADS) score trends among testicular cancer survivors: A longitudinal study.Org: University of Pennsylvania, Philadelphia, PA, PainReform,
Abstract
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.Org: University of Okahoma Health Sciences Center, Carolina BioOncology Institute, Sarah Cannon Research Institute/Tennessee Oncology, University of Michigan, START Midwest, Grand Rapids, MI,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Acute hospitalizations after proton beam therapy (PBT) versus intensity-modulated radiotherapy (IMRT) for locally advanced non–small-cell lung cancer (LA-NSCLC) in the era of immune checkpoint inhibitor (ICI) consolidation: A retrospective propensity score weighted study.Org: University of Pennsylvania, University of Pennsylvania Health System, New York Proton Center,
Abstract
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.Org: University of California San Diego Medical Center, La Jolla, CA, Wake Forest University School of Medicine, University of California San Francisco, University of Rochester Medical Center Department of Medical Oncology, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).Org: Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Active Biotech,
Abstract
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.Org: University of Pennsylvania, University of Pennsylvania Health System, Perelman School of Medicine, University of Pennsylvania,
Abstract
Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.Org: Tempus Labs, Inc., University of Pennsylvania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,
Abstract
Phase II study of telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, University of Pennsylvania, Weill Cornell Medical College University, University of Pennsylvania Health System,
Abstract
Are we ready to mitigate time toxicity of cancer care? Oncologists’ perceptions on digital interventions to fast-track cancer care.Org: Memorial Sloan Kettering Cancer Center, Penn Abramson Cancer Center, Abramson Cancer Center, University of Pennsylvania, Department of Family Medicine & Community Health, PSOM, University of Pennsylvania Health System,
Abstract
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,
Abstract
Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).Org: University of Pennsylvania, Philadelphia, PA, PainReform, CVS Health, Perelman School of Medicine,
Abstract
Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.Org: Abramson Cancer Center, Dana-Farber Cancer Institute, University of Wisconsin SMPH, Department of Radiology, University of Wisconsin Carbone Cancer Center, Brown University School of Public Health,
Abstract
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.Org: University of Colorado Cancer Center, The University of Pennsylvania, University of Pittsburgh, Pittsburgh, PA, University of Pennsylvania, University of Colorado Denver Anschutz Medical Center,
Abstract
Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Hillman Cancer Center, Pittsburgh, PA, Pittsburgh, PA, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, MA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Implementation strategies for monitoring adherence in real time (iSMART): A pilot randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Memora Health, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.Org: University of Pennsylvania, NYU Langone Medical Center, Vanderbilt University Medical Center, University of Chicago, Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic,
Abstract
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.Org: University of Pennsylvania, Basser Center for BRCA, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic,
Abstract
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Princess Margaret Cancer Centre, University of Toronto,
Abstract
Preliminary outcomes of a financial navigation program among lower socioeconomic patients with cancer.Org: School of Social Policy & Practice, University of Pennsylvania, Sidney Kimmel Cancer Center at Thomas Jefferson University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA,
Abstract
Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, University of California Irvine, San Diego State University Department of Biology, San Diego, CA, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey,
Abstract
Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC).Org: ConcertAI, Perelman School of Medicine, University of Pennsylvania,
Abstract
Clinical factors associated with successful liquid tumor biopsy in men with prostate cancer.Org: Department of Veterans Affairs James Hailey Hospital, University of California Los Angeles, US Department of Veterans Affairs, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington Medical Center,
Abstract
Evaluating clinical trial inclusion/exclusion criteria from claims using generative artificial intelligence.Org: ConcertAI, Perelman School of Medicine, University of Pennsylvania,
Abstract
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University of Colorado Denver Anschutz Medical Center, Aurora, CO,
Abstract
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.Org: Children’s Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania, Children's Hospital Los Angeles Department of Pediatrics, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital,
Abstract
Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems.Org: University of Pennsylvania-Abramson Cancer Center, VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, VA Salt Lake City Health Care, University of Pennsylvania,
Abstract
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.Org: University of Pennsylvania, Department of Medicine (Hematology - Oncology Division), Perelman School of Medicine, University of Pennsylvania,
Abstract
The COVID-19 pandemic's impact on diagnosis of cancers detectable through screening.Org: Perelman School of Medicine, University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Plasma KIM-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes.Org: Dana-Farber Cancer Institute, N.N. Blokhin National Medical Research Centre of Oncology, International Agency for Research on Cancer, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2- advanced breast cancer (aBC).Org: ConcertAI, Perelman School of Medicine, University of Pennsylvania,
Abstract
Cost of care associated with utilization of telehealth in clinical trials.Org: University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Division of Gynecologic Oncology, University of Pennsylvania, Harvard Medical School, Division of Urogynecology,
Abstract
Meta-analysis of gastrointestinal adverse effects in patients with non-small cell lung cancer treated with a combination therapy of pembrolizumab and chemotherapy versus chemotherapy alone.Org: Crozer Chester Medical Center, University of Pennsylvania, Crozer-Chester Medical Center,
Abstract
Identifying and addressing barriers to screening mammography in a medically underserved community.Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania Health System,
Abstract
Castration-resistant prostate cancer (CRPC) on PSMA-PET: Imaging features, disease distribution, and a comparison to castration-sensitive prostate cancer (CSPC).Org: Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Hospital of the University of Pennsylvania, Abramson Cancer Center and Perelman School of Medicine,
Abstract
Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.Org: NYU Langone Health, New York, NY, Cleveland Clinic Taussig Cancer Instititute, University of Pennsylvania, Delfi Diagnostics, Inc., The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, Fred Hutchinson Cancer Center, Seattle, WA, Virginia Oncology Associates, Hampton, VA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, Allegheny Health Network Cancer Institute, Pittsburgh, PA, University of California San Diego, La Jolla, CA, Dana-Farber Cancer Institute, Boston, MA, Indiana University Health Arnett Cancer Center, Lafayette, IN, University at Buffalo, Buffalo, NY, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Oregon Health and Science University Knight Cancer Institute, Portland, OR, University of Chicago, Chicago, IL,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Health equity challenges facing testing, evaluation, and implementation of multi-cancer early detection tests.Org: University of Chicago, University of Washington and Fred Hutchinson Cancer Research Centre, Perelman School of Medicine, University of Pennsylvania, Milken Institute School of Public Health,
Abstract
Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy.Org: University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Abramson Cancer Center, University of Pennsylvania,
Abstract
Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA,
Abstract
Feasibility of integrating geriatric oncology and palliative care assessment into the routine care of older adults in a community setting.Org: University of Pennsylvania, Penn Medicine Princeton Health, Abramson Cancer Center,
Abstract
Biochemical recurrence after salvage prostate bed radiotherapy captured on PSMA-PET: Patient characteristics and distribution of recurrent disease.Org: Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Hospital of the University of Pennsylvania, University of Pennsylvania,
Abstract
Serum IL-6 levels following siltuximab administration in Castleman disease.Org: Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, University of Arkansas for Medical Sciences (UAMS), Department of Medicine, Icahn School of Medicine at Mount Sinai, Perelman School of Medicine,
Abstract
Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.Org: Dana-Farber Cancer Institute, University of Colorado Anschutz Medical Campus, Harvard Medical School, University of Colorado Boulder, University of Pennsylvania,
Abstract
Impact of pandemic on accrual of minority participants to interventional cancer clinical trials.Org: Abramson Cancer Center, Abramson Cancer Center and Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, University of Pennsylvania,
Abstract
Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Michigan, Rogel Cancer Center, University of Michigan School of Social Work, University of Pennsylvania,
Abstract
External validation of biomechanical computed tomography for fracture risk classification in metastatic hormone sensitive prostate cancer.Org: MD Anderson Cancer Center, University of Pennsylvania School of Medicine, University of Pennsylvania, O.N. Diagnostics, University of California, Berkeley,
Abstract
A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositisOrg: Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Corbus Pharmaceuticals, Inc.,
Abstract
A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITISOrg: University of Pennsylvania, University of Cambridge, ChemoCentryx, Inc.,
Clinical trial
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 - Effect of FenofibrateStatus: Completed, Estimated PCD: 2022-05-10